Sulpiride versus placebo for schizophrenia

Area of Science:

• Psychiatry and Pharmacology
• Clinical Trial Analysis

Background:

• Sulpiride, an older antipsychotic, is noted for low adverse effects and efficacy in negative schizophrenia symptoms.
• It shares a neuropharmacological profile with newer atypical antipsychotics and is cost-effective.

Purpose of the Study:

• To evaluate the efficacy of sulpiride against placebo in treating schizophrenia and similar serious mental illnesses.
• The primary outcome was a clinically significant improvement in global state.

Main Methods:

• Searched Cochrane Schizophrenia Group Trials Register and references up to November 2012.
• Included randomized controlled trials (RCTs) comparing sulpiride with placebo.
• Analyzed dichotomous data using risk ratios (RR) and continuous data using mean differences (MD), both with 95% confidence intervals (CI).

Main Results:

• Two short-duration trials (n=113) were included; no new trials were found in the 2012 update.
• No studies reported on the primary outcome (global state response) or key secondary outcomes (quality of life, adverse effects).
• No clear differences in positive or negative symptoms were observed; meta-analysis was limited due to very low-quality evidence and skewed data.

Conclusions:

• Sulpiride shows potential as an antipsychotic, but randomized trial evidence for its superiority over placebo is very limited.
• Current clinical practice must rely on evidence beyond these trials until more robust data become available.